1. Abdel-Rahmann, H., Adams, J. P., Boyes, A. L., Kelly, M. J., Lamont, R. B., Mansfield, D. J., Proco-piou, P. A., Roberts, S. M., and Slee, D. H. 1994, Synthesis of a novel spirocyclic lactone in a potential route to squalestatin 1, J. Chem. Soc, Perkin Trans. 1, 1259–1262.
2. Abe, I., Tomesch, J. C., Wattanasin, S., and Prestwich, G. D., 1994, Inhibitors of squalene biosynthesis and metabolism: reviewing the literature published from January 1988 to September 1993, Nat. Prod. Rep. 11:279–301.
3. Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P., and Ganz, P., 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, New Engl. J. Med. 332:488–493.
4. Arai, M., Serzawa, N., and Terahara, S., 1988, Pravastatin sodium (CS-514), a novel cholesterol-lowering agent which inhibits HMG-CoA reductase, Annu. Rep. Sankyo Res. Lab. 40:1–38.
5. Ashwell, G., and Morell, A. G., 1974, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins, Adv. Enzymol. 41:99–128.